Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.

Details

Serval ID
serval:BIB_14EBB51169F2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.
Journal
Oncology letters
Author(s)
Bobrowicz M., Slusarczyk A., Domagala J., Dwojak M., Ignatova D., Chang Y.T., Iselin C., Miazek-Zapala N., Marhelava K., Guenova E., Winiarska M.
ISSN
1792-1074 (Print)
ISSN-L
1792-1074
Publication state
Published
Issued date
07/2020
Peer-reviewed
Oui
Volume
20
Number
1
Pages
533-540
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Histone deacetylase (HDAC) inhibitors, approved for the treatment of cutaneous T-cell lymphoma (CTCL), are non-selective agents associated with an unsatisfactory response and considerable side-effects. Targeting single HDAC isoforms is considered to provide novel therapeutic options. HDAC6 is overexpressed in primary samples from patients with CTCL and preclinical studies using transgenic mice that spontaneously develop a CTCL-like disease, have suggested that combinations including HDAC6 inhibitors may be successful in the treatment of CTCL. PI3K inhibition is currently being tested in clinical trials for CTCL with promising results. Since HDAC6 is known to diminish the activity of Akt via its deacetylation, the aim of the present study was to evaluate the therapeutic potential of selective HDAC6 inhibitors in combination with PI3K inhibitors in CTCL. Through the genetic and pharmacological inhibition of HDAC6, it was demonstrated that combining HDAC6 with PI3K inhibition may be an attractive therapeutic option for patients with CTCL.
Keywords
CTCL, HDAC6, PI3K, targeted therapy
Pubmed
Open Access
Yes
Create date
03/07/2020 18:49
Last modification date
05/08/2020 5:26
Usage data